Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

ClinicalTrials.gov ID: NCT01880320

Public ClinicalTrials.gov record NCT01880320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris

Study identification

NCT ID
NCT01880320
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
503 participants

Conditions and interventions

Conditions

Interventions

  • CD0271 0.3% / CD1579 2.5% Drug
  • CD0271 0.1% / CD1579 2.5% Drug
  • Topical Gel Vehicle Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2013
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update posted
Jun 27, 2018

2013 – 2014

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Galderma Investigational site Birmingham Alabama
Galderma Investigationnal Site Mobile Alabama
Galderma investigational Site Hot Springs Arkansas
Galderma Investigational Site Los Angeles California
Galderma Investigational Site Sacramento California
Galderma Investigational Site Santa Monica California
Galderma Investigational Site Miami Florida
Galderma Investigational Site Miramar Florida
Galderma Investiogational Site Newnan Georgia
Galderma Investigational Site Snellville Georgia
Galderma Investigational Site Chicago Illinois
Galderma Investigational Site Detroit Michigan
Galderma Investigational Site Albuquerque New Mexico
Galderma Investigational Site New York New York
Galderma Investigational Site Stony Brook New York
Galderma Investigational Site Raleigh North Carolina
Galderma Investigational Site Beachwood Ohio
Galderma investigational Site Hershey Pennsylvania
Galderma Investigational Site Greenville South Carolina
Galderma Investigational Site Goodlettsville Tennessee
Galderma Investigational Site Knoxville Tennessee
Galderma Investigational Site Arlington Texas
Galderma Investigational Site San Antonio Texas
Galderma Investigational Site Salt Lake City Utah
Galderma Investigational Site Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01880320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2018 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01880320 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →